Cargando…

Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study

Objective To determine the optimal range of increase in haemoglobin concentration with treatment with erythropoietins that is safe and is not associated with mortality. Design Retrospective cohort study. The analysis was adjusted for several covariables with Cox regression analysis with spline funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinze, Georg, Kainz, Alexander, Hörl, Walter H, Oberbauer, Rainer
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766440/
https://www.ncbi.nlm.nih.gov/pubmed/19854839
http://dx.doi.org/10.1136/bmj.b4018
_version_ 1782173218251997184
author Heinze, Georg
Kainz, Alexander
Hörl, Walter H
Oberbauer, Rainer
author_facet Heinze, Georg
Kainz, Alexander
Hörl, Walter H
Oberbauer, Rainer
author_sort Heinze, Georg
collection PubMed
description Objective To determine the optimal range of increase in haemoglobin concentration with treatment with erythropoietins that is safe and is not associated with mortality. Design Retrospective cohort study. The analysis was adjusted for several covariables with Cox regression analysis with spline functions. Use of erythropoietins, haemoglobin concentration, and covariables were included in a time varying manner; variable selection was based on the purposeful selection algorithm. Setting Transplantation centres in Austria. Participants 1794 renal transplant recipients recorded in the Austrian Dialysis and Transplant Registry who received a transplant between 1 January 1992 and 31 December 2004 and survived at least three months. Main outcome measures Survival time and haemoglobin concentration after treatment with erythropoietins. Results The prevalence of use of erythropoietins has increased over the past 15 years to 25%. Unadjusted extended Kaplan-Meier analysis suggests higher mortality in patients treated with erythropoietins, in whom 10 year survival was 57% compared with 78% in those not treated with erythropoietins (P<0.001). In the treated patients there were 5.4 events/100 person years, compared with 2.6 events/100 person years in those not treated (P<0.001). After adjustment for confounding by indication, comorbidities, comedication, and laboratory readings, haemoglobin concentrations >125 g/l were associated with increased mortality in treated patients (hazard ratio 2.8 (95% confidence interval 1.0 to 7.9) for haemoglobin concentration 140 g/l v 125 g/l), but not in those not treated (0.7, 0.4 to 1.5). When haemoglobin concentrations were 147 g/l or above, patients treated with erythropoietins showed significantly higher mortality than those who were not treated (3.0, 1.0 to 9.4). Conclusion Increasing haemoglobin concentrations to above 125 g/l with erythropoietins in renal transplant recipients is associated with an increase in mortality. This increase was significant at concentrations above 140 g/l.
format Text
id pubmed-2766440
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-27664402009-12-30 Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study Heinze, Georg Kainz, Alexander Hörl, Walter H Oberbauer, Rainer BMJ Research Objective To determine the optimal range of increase in haemoglobin concentration with treatment with erythropoietins that is safe and is not associated with mortality. Design Retrospective cohort study. The analysis was adjusted for several covariables with Cox regression analysis with spline functions. Use of erythropoietins, haemoglobin concentration, and covariables were included in a time varying manner; variable selection was based on the purposeful selection algorithm. Setting Transplantation centres in Austria. Participants 1794 renal transplant recipients recorded in the Austrian Dialysis and Transplant Registry who received a transplant between 1 January 1992 and 31 December 2004 and survived at least three months. Main outcome measures Survival time and haemoglobin concentration after treatment with erythropoietins. Results The prevalence of use of erythropoietins has increased over the past 15 years to 25%. Unadjusted extended Kaplan-Meier analysis suggests higher mortality in patients treated with erythropoietins, in whom 10 year survival was 57% compared with 78% in those not treated with erythropoietins (P<0.001). In the treated patients there were 5.4 events/100 person years, compared with 2.6 events/100 person years in those not treated (P<0.001). After adjustment for confounding by indication, comorbidities, comedication, and laboratory readings, haemoglobin concentrations >125 g/l were associated with increased mortality in treated patients (hazard ratio 2.8 (95% confidence interval 1.0 to 7.9) for haemoglobin concentration 140 g/l v 125 g/l), but not in those not treated (0.7, 0.4 to 1.5). When haemoglobin concentrations were 147 g/l or above, patients treated with erythropoietins showed significantly higher mortality than those who were not treated (3.0, 1.0 to 9.4). Conclusion Increasing haemoglobin concentrations to above 125 g/l with erythropoietins in renal transplant recipients is associated with an increase in mortality. This increase was significant at concentrations above 140 g/l. BMJ Publishing Group Ltd. 2009-10-23 /pmc/articles/PMC2766440/ /pubmed/19854839 http://dx.doi.org/10.1136/bmj.b4018 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Research
Heinze, Georg
Kainz, Alexander
Hörl, Walter H
Oberbauer, Rainer
Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
title Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
title_full Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
title_fullStr Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
title_full_unstemmed Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
title_short Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
title_sort mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766440/
https://www.ncbi.nlm.nih.gov/pubmed/19854839
http://dx.doi.org/10.1136/bmj.b4018
work_keys_str_mv AT heinzegeorg mortalityinrenaltransplantrecipientsgivenerythropoietinstoincreasehaemoglobinconcentrationcohortstudy
AT kainzalexander mortalityinrenaltransplantrecipientsgivenerythropoietinstoincreasehaemoglobinconcentrationcohortstudy
AT horlwalterh mortalityinrenaltransplantrecipientsgivenerythropoietinstoincreasehaemoglobinconcentrationcohortstudy
AT oberbauerrainer mortalityinrenaltransplantrecipientsgivenerythropoietinstoincreasehaemoglobinconcentrationcohortstudy